US and Cuban biomedical researchers are free to collaborate

first_imgAficionados of cigars and rum are celebrating new U.S. rules that allow visitors to Cuba to carry home as much as these fine commodities as they can cram into their luggage. But the regulations, unveiled today and set to take effect on 17 October, are sure to please another constituency: researchers in biomedicine and public health. The U.S. Department of the Treasury has authorized U.S. scientists to freely collaborate with Cuban counterparts on everything from cancer therapies to combatting the Zika virus.“It is a very important step,” says neuroscientist Pedro Valdés-Sosa, research director at the Cuban Neuroscience Center in Havana. On a trip last month to the United States, he says, “everywhere I went there were concrete ideas for collaborations that would benefit the people of both countries. These new measures pave the way for cooperation.”The rules, which build on the historic rapprochement between the two nations in December 2014, also make it easier for Cuban-made pharmaceuticals to undergo U.S. Food and Drug Administration (FDA) review, and they allow FDA-approved Cuban drugs to be imported and sold. In a potential boon for Cuban scientists of all stripes, the U.S. government is also lifting restrictions that have mostly barred Cubans from receiving U.S. grants, scholarships, and awards for research. Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Email Sign up for our daily newsletter Get more great content like this delivered right to you! Countrycenter_img Click to view the privacy policy. Required fields are indicated by an asterisk (*) “If it’s truly feasible to use federal grants to support Cuban research, then everybody wins,” says immunologist Thomas Schwaab, chief of strategy, business development and outreach at Roswell Park Cancer Institute in Buffalo, New York. Roswell Park has been working with the Center of Molecular Immunology (CIM) in Havana to shepherd a Cuba-developed lung cancer vaccine into clinical trials in the United States.Under earlier rules, U.S. scientists had to apply to the treasury’s Office of Foreign Assets Control (OFAC) for a license to conduct research with Cuban colleagues—“a very involved and detailed process,” Schwaab says. Most licenses are valid for only 1 or 2 years at most, he says, and renewals are time consuming, making it hard to sustain long-term collaborations.The longstanding OFAC restrictions created “a lot of confusion” over what kinds of collaborations are permissible, adds Marga Gual Soler, a project director at the AAAS Center for Science Diplomacy, which has brokered contacts in recent years between Cuban and U.S. researchers. (AAAS is the publisher of Science.) It has been unclear, she says, “what activities required special OFAC licenses, especially when it comes to carrying or donating scientific equipment to Cuba.”Roswell Park did obtain an OFAC license to conduct preclinical and clinical research on CimaVax EGF, a therapeutic lung cancer vaccine developed by CIM that has been used in more than 4000 patients worldwide. “Cuban science has taken a completely novel approach to immunotherapy, and they have developed totally different solutions,” Schwaab says. He hopes the new rules will now help Roswell Park gain FDA approval for a clinical trial in U.S. patients with advanced lung cancer.One open question is whether Cuba’s own regulations will pose unanticipated constraints. “It’s one thing for us to say we want to collaborate,” Schwaab says. Another uncertainty is whether many of Cuba’s top scientists, who have forged collaborations with colleagues in Europe and elsewhere, will embrace working with a country that sought to isolate them for so long. Despite the embargo, Schwaab notes, Cuban scientists “are very proud of what they’ve achieved.”last_img

Leave a Reply

Your email address will not be published. Required fields are marked *